Simplex Trading’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $250 | Buy |
+200
| New | +$421 | ﹤0.01% | 9009 |
|
|
2026
Q1 | – | Sell |
-200
| Closed | -$860 | – | 10453 |
|
|
2025
Q4 | $860 | Sell |
200
-17,100
| -99% | -$153K | ﹤0.01% | 8060 |
|
|
2025
Q3 | $674K | Buy |
+17,300
| New | +$493K | ﹤0.01% | 3476 |
|
|
2024
Q1 | – | Sell |
-117
| Closed | -$3K | – | 10132 |
|
|
2023
Q4 | $3K | Hold |
117
| – | – | ﹤0.01% | 8180 |
|
|
2023
Q3 | $7K | Sell |
117
-127
| -52% | -$11.9K | ﹤0.01% | 7481 |
|
|
2023
Q2 | $24K | Buy |
244
+52
| +27% | +$7.16K | ﹤0.01% | 6608 |
|
|
2023
Q1 | $33K | Sell |
192
-183
| -49% | -$61.3K | ﹤0.01% | 6409 |
|
|
2022
Q4 | $144K | Sell |
375
-31
| -8% | -$11.8K | ﹤0.01% | 4649 |
|
|
2022
Q3 | $136K | Sell |
406
-63
| -13% | -$22.8K | ﹤0.01% | 5105 |
|
|
2022
Q2 | $154K | Sell |
469
-678
| -59% | -$238K | ﹤0.01% | 4960 |
|
|
2022
Q1 | $501K | Buy |
1,147
+255
| +29% | +$105K | ﹤0.01% | 3841 |
|
|
2021
Q4 | $390K | Sell |
892
-811
| -48% | -$408K | ﹤0.01% | 4170 |
|
|
2021
Q3 | $885K | Hold |
1,703
| – | – | ﹤0.01% | 3252 |
|
|
2021
Q2 | $874K | Buy |
1,703
+1,682
| +8,010% | +$1.07M | ﹤0.01% | 3310 |
|
|
2021
Q1 | $1.61M | Sell |
21
-24
| -53% | -$16.4K | ﹤0.01% | 1860 |
|
|
2020
Q4 | $2.45M | Buy |
45
+36
| +400% | +$18.9K | ﹤0.01% | 1565 |
|
|
2020
Q3 | $403K | Sell |
9
-2
| -18% | -$1.16K | ﹤0.01% | 3255 |
|
|
2020
Q2 | $672K | Buy |
11
+6
| +120% | +$3.31K | ﹤0.01% | 2550 |
|
|
2020
Q1 | $254K | Sell |
5
-2
| -29% | -$1.09K | ﹤0.01% | 3317 |
|
|
2019
Q4 | $423K | Buy |
7
+4
| +133% | +$2.81K | ﹤0.01% | 2916 |
|
|
2019
Q3 | $219K | Sell |
3
-9
| -75% | -$7.48K | ﹤0.01% | 3468 |
|
|
2019
Q2 | $896K | Buy |
12
+6
| +100% | +$4.22K | ﹤0.01% | 2002 |
|
|
2019
Q1 | $445K | Buy |
6
+2
| +50% | +$1.2K | ﹤0.01% | 2776 |
|
|
2018
Q4 | $209K | Sell |
4
-3
| -43% | -$1.94K | ﹤0.01% | 3124 |
|
|
2018
Q3 | $644K | Sell |
7
-41
| -85% | -$29.6K | ﹤0.01% | 2354 |
|
|
2018
Q2 | $3.31M | Buy |
48
+43
| +860% | +$21.9K | 0.01% | 791 |
|
|
2018
Q1 | $26K | Sell |
5
-6
| -55% | -$2.91K | ﹤0.01% | 3104 |
|
|
2017
Q4 | $33K | Sell |
11
-2
| -15% | -$912 | ﹤0.01% | 2839 |
|
|
2017
Q3 | $51K | Sell |
13
-9
| -41% | -$4.51K | ﹤0.01% | 2288 |
|
|
2017
Q2 | $140K | Buy |
22
+14
| +175% | +$8.88K | 0.01% | 1479 |
|
|
2017
Q1 | $181K | Buy |
8
+5
| +167% | +$2.67K | 0.01% | 1281 |
|
|
2016
Q4 | $13K | Sell |
3
-20
| -87% | -$6.42K | ﹤0.01% | 3491 |
|
|
2016
Q3 | $127K | Buy |
23
+20
| +667% | +$4.33K | 0.01% | 1363 |
|
|
2016
Q2 | $9K | Buy |
+3
| New | +$653 | ﹤0.01% | 3719 |
|
|
2016
Q1 | – | Hold |
0
| – | -$3K | – | 6386 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 4332 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 4227 |
|
|
2015
Q2 | – | Sell |
-1
| Closed | -$386 | – | 4393 |
|
|
2015
Q1 | $3K | Buy |
+1
| New | +$378 | ﹤0.01% | 3929 |
|
Other funds holding TVRD
NFL
Simplex Trading's TVRD Position: Q3 2026 in Review
Simplex Trading opened a new position in Tvardi Therapeutics (TVRD) in Q3 2026: 36 shares worth $45. The stake represents ﹤0.01% of the portfolio and ranks #9089 among its holdings. This is a return to the name: Simplex Trading previously reported a position in TVRD as recently as Q4 2025.
Simplex Trading first reported a position in TVRD in Q1 2016 and has held it in 32 quarters since. The position peaked at $447K in Q3 2018. 14 funds tracked by Wall St. Rank hold TVRD as of Q3 2026.
- Simplex Trading held 36 shares of Tvardi Therapeutics worth $45 as of Q3 2026.
- Tvardi Therapeutics was a new Simplex Trading position in Q3 2026.
- Tvardi Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #9089 holding.
- Simplex Trading first reported a position in Tvardi Therapeutics in Q1 2016 and has held it in 32 quarters since.
- Simplex Trading's Tvardi Therapeutics position peaked at $447K in Q3 2018.
- 14 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2026.
Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.